All In Biotech

Drug Trial Radar · NCT05906576

Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 21, 2023

Primary completion

Nov 2026

Study completion Feb 2027

Sponsor

Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.

Conditions

  • Crohn Disease

Interventions

  • InfliximabDrug

    Infliximab in the treatment of Crohn's disease in children

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical response rate at 14 weeksTime frame: up to 14 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.